Showing results (241-250 of 276) with videos related to

Sort By:
Pageof 28
Human Gene Therapy|May 6, 2005
Adeno-associated virus pseudotype 5 vector improves gene transfer in arthritic jointsF Apparailly, M Khoury, M J B Vervoordeldonk, et al.
Clinical Immunology and Immunopathology|October 1, 1994
Expression of granzymes A and B in synovial tissue from patients with rheumatoid arthritis and osteoarthritisJ A Kummer, P P Tak, B M Brinkman, et al.
Annals of the Rheumatic Diseases|July 16, 2008
Exposure to nuclear antigens contributes to the induction of humoral autoimmunity during tumour necrosis factor alpha blockadeT Cantaert, L De Rycke, C P Mavragani, et al.
Annals of the Rheumatic Diseases|February 14, 2004
Activation of the STAT1 pathway in rheumatoid arthritisP V Kasperkovitz, N L Verbeet, T J Smeets, et al.
Genes and Immunity|June 18, 2010
Pharmacogenomics of infliximab treatment using peripheral blood cells of patients with rheumatoid arthritisL G M van Baarsen, C A Wijbrandts, D M Gerlag, et al.
Annals of the Rheumatic Diseases|March 17, 2007
Reduction of arthritis following intra-articular administration of an adeno-associated virus serotype 5 expressing a disease-inducible TNF-blocking agentJ Adriaansen, M Khoury, C J de Cortie, et al.
Clinical Rheumatology|April 9, 2017
Single vagus nerve stimulation reduces early postprandial C-peptide levels but not other hormones or postprandial metabolismM W Tang, F S van Nierop, F A Koopman, et al.
Scandinavian Journal of Rheumatology|September 3, 2014
E-health to improve work functioning in employees with rheumatoid arthritis in rheumatology practice: a feasibility studyJ L Hoving, I Zoer, M van der Meer, et al.
Annals of the Rheumatic Diseases|August 4, 2010
Decrease in immunoglobulin free light chains in patients with rheumatoid arthritis upon rituximab (anti-CD20) treatment correlates with decrease in disease activityT Groot Kormelink, J Tekstra, R M Thurlings, et al.
Annals of the Rheumatic Diseases|July 10, 2004
A multicentre, randomised, double blind, placebo controlled phase II study of subcutaneous interferon beta-1a in the treatment of patients with active rheumatoid arthritisJ van Holten, K Pavelka, J Vencovsky, et al.
Pageof 28